{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:47:33Z","timestamp":1791582453528,"version":"4.3.4"},"reference-count":166,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"unspecified","delay-in-days":82,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Expert Rev. Mol. Med."],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous multi-organ manifestations and poorly understood pathogenesis. The variable therapeutic outcomes and potential for cross-indication treatments underscore the need to identify pivotal disease-driving signalling pathways for developing innovative and safer regimens. By categorizing the pathogenesis of SLE into three interconnected stages involving over-activated immune response, skewed cytokine homeostasis and impaired debris clearance, and by analysing public clinical data, this review posits that the Janus kinase\u2013signal transducer and activator of transcription axis is a central driver of SLE pathogenesis. Accordingly, it explores the potential of cold atmospheric plasma to modulate this pathway for therapeutic benefit that requires further experimental and clinical validations.<\/jats:p>","DOI":"10.1017\/erm.2026.10042","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:32:27Z","timestamp":1774326747000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":1,"title":["Targeting JAK\/STAT signalling with cold atmospheric plasma: a potential therapy for systemic lupus erythematosus"],"prefix":"10.1017","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0006-4042","authenticated-orcid":false,"given":"Xiaofeng","family":"Dai","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zhmm22","id-type":"ROR","asserted-by":"publisher"}],"name":"First Affiliated Hospital of Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Fan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/035y7a716","id-type":"ROR","asserted-by":"publisher"}],"name":"The Affiliated Hospital of Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizheng","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zhmm22","id-type":"ROR","asserted-by":"publisher"}],"name":"First Affiliated Hospital of Xi\u2019an Jiaotong University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"S1462399426100428_r145","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060842"},{"key":"S1462399426100428_r10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61519-1"},{"key":"S1462399426100428_r11","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-023-01911-5"},{"key":"S1462399426100428_r76","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0386-6"},{"key":"S1462399426100428_r57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218636"},{"key":"S1462399426100428_r85","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1514-3"},{"key":"S1462399426100428_r150","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-022-01703-3"},{"key":"S1462399426100428_r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.11.001"},{"key":"S1462399426100428_r54","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)00583-4"},{"key":"S1462399426100428_r134","doi-asserted-by":"publisher","DOI":"10.1002\/ppap.201800052"},{"key":"S1462399426100428_r135","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2018.06.010"},{"key":"S1462399426100428_r24","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0090"},{"key":"S1462399426100428_r8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16744-9"},{"key":"S1462399426100428_r113","doi-asserted-by":"publisher","DOI":"10.1109\/TRPMS.2024.3349571"},{"key":"S1462399426100428_r124","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101597"},{"key":"S1462399426100428_r151","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-022-05435-0"},{"key":"S1462399426100428_r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107575"},{"key":"S1462399426100428_r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.12.001"},{"key":"S1462399426100428_r141","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"S1462399426100428_r35","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854"},{"key":"S1462399426100428_r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157425"},{"key":"S1462399426100428_r60","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00963"},{"key":"S1462399426100428_r87","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"S1462399426100428_r130","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14257"},{"key":"S1462399426100428_r38","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.150"},{"key":"S1462399426100428_r63","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06422.x"},{"key":"S1462399426100428_r166","unstructured":"166. ClinicalTrials.gov (2019) Efficacy and safety of artesunate plus standard of care in active lupus nephritis (AURORA). Available at https:\/\/clinicaltrials.gov\/study\/NCT03214731 (accessed 12 November 2024)."},{"key":"S1462399426100428_r75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.026"},{"key":"S1462399426100428_r103","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152965"},{"key":"S1462399426100428_r133","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2018.04.003"},{"key":"S1462399426100428_r3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819"},{"key":"S1462399426100428_r137","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116657"},{"key":"S1462399426100428_r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.01.018"},{"key":"S1462399426100428_r107","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00652-8"},{"key":"S1462399426100428_r68","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.1.399"},{"key":"S1462399426100428_r56","first-page":"453","article-title":"Oxidative stress contributes to inflammatory and cellular damage in systemic lupus erythematosus","volume":"16","author":"Yan","year":"2023","journal-title":"Cellular Markers and Molecular Mechanism. J Inflamm Res"},{"key":"S1462399426100428_r105","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2224625"},{"key":"S1462399426100428_r129","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20922709"},{"key":"S1462399426100428_r31","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"S1462399426100428_r138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130078"},{"key":"S1462399426100428_r159","unstructured":"159. ClinicalTrials.gov (2022) Evaluation of tofacitinib in prevention of photosensitivity in lupus. Available at https:\/\/clinicaltrials.gov\/study\/NCT05048238 (accessed January 2026)."},{"key":"S1462399426100428_r39","first-page":"316","article-title":"Therapy side effects in systemic lupus erythematosus","volume":"44","author":"Popa","year":"2018","journal-title":"Current Health Sciences Journal"},{"key":"S1462399426100428_r74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0337679100"},{"key":"S1462399426100428_r52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300570"},{"key":"S1462399426100428_r81","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07064.x"},{"key":"S1462399426100428_r73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.15.7673"},{"key":"S1462399426100428_r115","article-title":"Epithelial-to-mesenchymal transition enhances cancer cell sensitivity to cytotoxic effects of cold atmospheric plasmas in breast and bladder cancer systems","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"S1462399426100428_r165","first-page":"Cd007478","article-title":"Interventions for cutaneous disease in systemic lupus erythematosus","volume":"3","author":"Hannon","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S1462399426100428_r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2012.12.006"},{"key":"S1462399426100428_r27","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211073001"},{"key":"S1462399426100428_r13","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05183-4"},{"key":"S1462399426100428_r20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155421"},{"key":"S1462399426100428_r146","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15725-7"},{"key":"S1462399426100428_r125","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112936"},{"key":"S1462399426100428_r116","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102976"},{"key":"S1462399426100428_r22","doi-asserted-by":"publisher","DOI":"10.1002\/art.42840"},{"key":"S1462399426100428_r4","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"The Journal of Rheumatology"},{"key":"S1462399426100428_r1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2315"},{"key":"S1462399426100428_r29","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/ad4b24"},{"key":"S1462399426100428_r65","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.01.003"},{"key":"S1462399426100428_r98","unstructured":"98. A clinical trial to evaluate safety of gusacitinib in patients with systemic lupus erythematosus (SLE) or lupus. Available at https:\/\/clinicaltrials.gov\/study\/NCT06238531 (accessed 12 November 2024)."},{"key":"S1462399426100428_r30","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222486"},{"key":"S1462399426100428_r110","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2022.07.007"},{"key":"S1462399426100428_r79","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06756.x"},{"key":"S1462399426100428_r9","doi-asserted-by":"publisher","DOI":"10.1111\/jog.15726"},{"key":"S1462399426100428_r17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02043-2"},{"key":"S1462399426100428_r157","unstructured":"157. ClinicalTrials.gov (2022) Study of Ruxolitinib cream for the treatment of discoid lupus erythematosus. Available at https:\/\/clinicaltrials.gov\/study\/NCT04908280 (accessed January 2024)."},{"key":"S1462399426100428_r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.014"},{"key":"S1462399426100428_r50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221985"},{"key":"S1462399426100428_r80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.19.8831"},{"key":"S1462399426100428_r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102976"},{"key":"S1462399426100428_r71","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01468-7"},{"key":"S1462399426100428_r100","doi-asserted-by":"publisher","DOI":"10.1038\/7445"},{"key":"S1462399426100428_r82","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5A0416-194R"},{"key":"S1462399426100428_r109","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2018.06.001"},{"key":"S1462399426100428_r112","doi-asserted-by":"publisher","DOI":"10.1177\/1553350617691710"},{"key":"S1462399426100428_r144","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2024.11.028"},{"key":"S1462399426100428_r123","doi-asserted-by":"publisher","DOI":"10.1088\/2057-1976\/ad8200"},{"key":"S1462399426100428_r18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43650-z"},{"key":"S1462399426100428_r106","first-page":"1422","article-title":"STAT5 inhibitor attenuates atherosclerosis via inhibition of inflammation: The role of STAT5 in atherosclerosis","volume":"13","author":"Wang","year":"2021","journal-title":"American Journal of Translational Research"},{"key":"S1462399426100428_r147","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6463\/aa5dbb"},{"key":"S1462399426100428_r164","unstructured":"164. ClinicalTrials.gov (2023) A study to assess effectiveness and safety of deucravacitinib compared with placebo in participants with active systemic lupus erythematosus (SLE) (POETYK SLE-1). Available at https:\/\/clinicaltrials.gov\/study\/NCT05617677 (accessed 13 November 2024)."},{"key":"S1462399426100428_r143","doi-asserted-by":"publisher","DOI":"10.1080\/10715762.2017.1423069"},{"key":"S1462399426100428_r92","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02794-x"},{"key":"S1462399426100428_r91","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316640910"},{"key":"S1462399426100428_r42","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309102557"},{"key":"S1462399426100428_r16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035"},{"key":"S1462399426100428_r97","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391"},{"key":"S1462399426100428_r25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011286"},{"key":"S1462399426100428_r118","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13304"},{"key":"S1462399426100428_r72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.09.023"},{"key":"S1462399426100428_r94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6"},{"key":"S1462399426100428_r37","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05306-5"},{"key":"S1462399426100428_r96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23361-z"},{"key":"S1462399426100428_r84","doi-asserted-by":"publisher","DOI":"10.1126\/science.8140422"},{"key":"S1462399426100428_r70","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81167-8"},{"key":"S1462399426100428_r64","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker448"},{"key":"S1462399426100428_r62","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn8933"},{"key":"S1462399426100428_r49","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9943743"},{"key":"S1462399426100428_r161","unstructured":"161. ClinicalTrials.gov (2019) Long-term safety and efficacy study of deucravacitinib in participants with systemic lupus erythematosus. Available at https:\/\/clinicaltrials.gov\/study\/NCT03920267 (accessed 12 November 2024)."},{"key":"S1462399426100428_r148","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c21635"},{"key":"S1462399426100428_r32","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000297"},{"key":"S1462399426100428_r47","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae011"},{"key":"S1462399426100428_r121","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.105455"},{"key":"S1462399426100428_r46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07627-2"},{"key":"S1462399426100428_r117","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0541-z"},{"key":"S1462399426100428_r160","unstructured":"160. ClinicalTrials.gov (2017) Open-label study of tofacitinib for moderate to severe skin involvement in young adults with lupus. Available at https:\/\/clinicaltrials.gov\/study\/NCT03288324 (accessed January 2026)."},{"key":"S1462399426100428_r153","unstructured":"153. ClinicalTrials.gov (2023) Program to assess adverse events and change in disease activity of oral upadacitinib in adult participants with moderate to severe systemic lupus erythematosus (SELECT-SLE). Available at https:\/\/clinicaltrials.gov\/study\/NCT05843643 (accessed 11 November 2024)."},{"key":"S1462399426100428_r45","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02168-0"},{"key":"S1462399426100428_r26","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270"},{"key":"S1462399426100428_r67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900311"},{"key":"S1462399426100428_r69","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3519"},{"key":"S1462399426100428_r41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15389"},{"key":"S1462399426100428_r61","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.08.010"},{"key":"S1462399426100428_r83","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90235-6"},{"key":"S1462399426100428_r142","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2325-0"},{"key":"S1462399426100428_r126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052653"},{"key":"S1462399426100428_r12","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70628"},{"key":"S1462399426100428_r122","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204985"},{"key":"S1462399426100428_r86","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320950019"},{"key":"S1462399426100428_r156","unstructured":"156. ClinicalTrials.gov (2022) Efficiency of use of baracetinib in treatment of lupus nephritis. Available at https:\/\/clinicaltrials.gov\/study\/NCT05432531 (accessed 12 November 2024)."},{"key":"S1462399426100428_r59","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23"},{"key":"S1462399426100428_r163","unstructured":"163. ClinicalTrials.gov (2023) A study to evaluate effectiveness and safety of deucravacitinib (BMS-986165) compared with placebo in participants with active systemic lupus erythematosus (POETYK SLE-2). Available at https:\/\/clinicaltrials.gov\/study\/NCT05620407 (accessed 15 November 2024)."},{"key":"S1462399426100428_r158","unstructured":"158. ClinicalTrials.gov (2024) Study to evaluate the efficacy of ruxolitinib 1.5% cream in adult subjects with discoid lupus erythematosus. Available at https:\/\/clinicaltrials.gov\/study\/NCT06261021 (accessed 23 November 2024)."},{"key":"S1462399426100428_r102","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.04.004"},{"key":"S1462399426100428_r140","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1599-7"},{"key":"S1462399426100428_r36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149095"},{"key":"S1462399426100428_r101","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem001"},{"key":"S1462399426100428_r93","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02607-1"},{"key":"S1462399426100428_r108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113360"},{"key":"S1462399426100428_r40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1807382"},{"key":"S1462399426100428_r66","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123397"},{"key":"S1462399426100428_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102873"},{"key":"S1462399426100428_r119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.144142"},{"key":"S1462399426100428_r88","doi-asserted-by":"publisher","DOI":"10.1002\/art.42926"},{"key":"S1462399426100428_r15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16021"},{"key":"S1462399426100428_r2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41632"},{"key":"S1462399426100428_r5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"S1462399426100428_r89","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001490"},{"key":"S1462399426100428_r120","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70045"},{"key":"S1462399426100428_r111","doi-asserted-by":"publisher","DOI":"10.1109\/TRPMS.2024.3351743"},{"key":"S1462399426100428_r90","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab685"},{"key":"S1462399426100428_r104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031106"},{"key":"S1462399426100428_r78","doi-asserted-by":"publisher","DOI":"10.1038\/nri705"},{"key":"S1462399426100428_r139","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363210-00004"},{"key":"S1462399426100428_r155","unstructured":"155. ClinicalTrials.gov (2022) Use of baricitenib to maintain of remission. Available at https:\/\/clinicaltrials.gov\/study\/NCT05686746 (accessed 6 November 2024)."},{"key":"S1462399426100428_r154","unstructured":"154. ClinicalTrials.gov (2019) A study of baricitinib in participants with systemic lupus erythematosus (SLE) (SLE-BRAVE-X). Available at https:\/\/clinicaltrials.gov\/study\/NCT03843125 (accessed January 2026)."},{"key":"S1462399426100428_r152","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70396"},{"key":"S1462399426100428_r128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.04.019"},{"key":"S1462399426100428_r6","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305489"},{"key":"S1462399426100428_r55","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-020-00879-5"},{"key":"S1462399426100428_r99","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16639"},{"key":"S1462399426100428_r114","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.72296"},{"key":"S1462399426100428_r132","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.11.045"},{"key":"S1462399426100428_r23","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080898"},{"key":"S1462399426100428_r34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-043021-032611"},{"key":"S1462399426100428_r95","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2023.0027"},{"key":"S1462399426100428_r127","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102991"},{"key":"S1462399426100428_r136","doi-asserted-by":"publisher","DOI":"10.7150\/thno.70098"},{"key":"S1462399426100428_r44","doi-asserted-by":"publisher","DOI":"10.1186\/ar3546"},{"key":"S1462399426100428_r43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.04871.x"},{"key":"S1462399426100428_r58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098899"},{"key":"S1462399426100428_r162","unstructured":"162. ClinicalTrials.gov (2021) A study to evaluate efficacy and safety of deucravacitinib in participants with active discoid and\/or subacute cutaneous lupus erythematosus (DLE\/SCLE). Available at https:\/\/clinicaltrials.gov\/study\/NCT04857034 (accessed 12 November 2024)."},{"key":"S1462399426100428_r77","doi-asserted-by":"publisher","DOI":"10.1126\/science.8085155"},{"key":"S1462399426100428_r131","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14236"},{"key":"S1462399426100428_r149","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.102445"}],"container-title":["Expert Reviews in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1462399426100428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:11:48Z","timestamp":1784272308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1462399426100428\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":166,"alternative-id":["S1462399426100428"],"URL":"https:\/\/doi.org\/10.1017\/erm.2026.10042","relation":{},"ISSN":["1462-3994"],"issn-type":[{"value":"1462-3994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e27"}}